MedTrace Logo

Evaluation of K9 in Subjects With Thyroid Eye Disease (TED)

NCT06467435 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-04-01

No results posted yet for this study

Summary

The study is comprised of two cohorts. Cohort 1 will examine pharmacokinetics of K9 in 3 healthy volunteers over 24 hours. This cohort has been completed. Cohort 2 will involve up to 10 patients with TED. Patients will receive oral K9 BID for up to 24 weeks and will be followed up to a total of 26 weeks with a primary endpoint of safety.

Conditions

  • Thyroid Eye Disease

Interventions

DRUG

Kamuvudine-9

96 mg tablets taken twice a day for 24 weeks

DRUG

Kamuvudine-9

96 mg tablets taken once

Sponsors & Collaborators

  • Inflammasome Therapeutics

    collaborator INDUSTRY

  • Peter Timoney

    lead OTHER

Principal Investigators

  • Peter Timoney · University of Kentucky

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-06
Primary Completion
2026-02-23
Completion
2026-02-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06467435 on ClinicalTrials.gov